Colchicine or

Phase 3Small molecule

NNYU Langone Health

Colchicine or is one of 51 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

Acute MyocarditisRecruiting

Acute Coronary SyndromePreclinical

Active, not recruiting

Acute MyocarditisPhase 3

Recruiting

Competition

Competitive Landscape

53 competitors in Acute Coronary Syndrome

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

39 2

Brilinta

AstraZeneca

Approved

31 3

Crestor

AstraZeneca

Approved

11 4

Bayer Aspirin

Bayer

Approved

10 5

Colcrys

Jazz Pharmaceuticals

Approved

6 6

Effient

CCosette Pharmaceuticals, Inc.

Approved

19 7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

15 8

Leqvio

Novartis

Approved

3 9

Lescol

Novartis

Approved

2 10

Praluent

Regeneron

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

N/ARecruiting

Acute Coronary Syndrome

NCT06215989

Q3 2028

Phase 3Recruiting

Acute Myocarditis

NCT05855746

Q3 2030

Phase 2Recruiting

CPPD - Calcium Pyrophosphate Deposition Disease

NCT06855433

Clinical

Trials by Indication[1]

Osteoarthritis1 trial

Colchicine for the Treatment of Osteoarthritis of the Knee

Completed·NNYU Langone Health·Phase 4·NCT03913442·120 enrolled

Cardiac Surgery1 trial

COlchicine in Cardiac Surgery

Completed·BBakulev Scientific Center of Cardiovascular Surgery·Phase 4·NCT04224545·267 enrolled

CLE1 trial

CLEAR SYNERGY Neutrophil Substudy

Completed·NNYU Langone Health··NCT03874338·322 enrolled

Acute Myocarditis1 trial

Colchicine Versus Placebo in Acute Myocarditis Patients

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05855746·300 enrolled

Injury1 trial

Colchicine for Reduction of Periprocedural Myocardial Injury in Percutaneous Coronary Intervention

Unknown status·SSohag University··NCT05745818·300 enrolled

4 more indications

COVID-191 trial

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia

Completed·UUniversidad Nacional de Colombia·Phase 2/3·NCT04359095·650 enrolled

Acute Coronary Syndrome1 trial

Treatment of ACuTe Coronary Syndromes With Low-dose colchICine

Recruiting·—·N/A·NCT06215989·6,574 enrolled

CPPD - Calcium Pyrophosphate Deposition Disease1 trial

A Randomized, Double-Blind, Multi-Site Placebo Controlled Trial of Colchicine in Calcium Pyrophosphate Deposition Disease

Recruiting·BBrigham and Women's Hospital·Phase 2·NCT06855433·150 enrolled

Intracranial Hemorrhages1 trial

A Vanguard, Double-blind, Randomized, Placebo-controlled, Phase 2 Pilot Study to Investigate Prevention of Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous ICH and Established, or Risk Factors for, Atherosclerosis

Completed·PPopulation Health Research Institute·Phase 2·NCT05159219·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Colchicine or. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Colchicine or compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Colchicine or. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNYU Langone Health

Colchicine or

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q3 2030

Trials by Indication[1]

Osteoarthritis1 trial

Cardiac Surgery1 trial

CLE1 trial

Acute Myocarditis1 trial

Injury1 trial

COVID-191 trial

Acute Coronary Syndrome1 trial

CPPD - Calcium Pyrophosphate Deposition Disease1 trial

Intracranial Hemorrhages1 trial

References

Drug Info

Quick Facts

Related News